BlossomHill Therapeutics rallies $71m Series A

BlossomHill Therapeutics Inc, a biopharmaceutical company focusing on oncology and autoimmune disorders, has raised $71 million in Series A financing.

ByIris Dorbian

4 March 2021•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Deals Healthcare Briefs

BlossomHill Therapeutics rallies $71m Series A

Cormorant Asset Management

OrbiMed Advisors

Vivo Capital

Related articles